Skip to main content
. 2023 Mar 6;10(1):e001508. doi: 10.1136/bmjresp-2022-001508

Figure 2.

Figure 2

Flow diagram of patient inclusion in study. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting beta agonist; SAMA, short-acting muscarinic antagonist.